P-glycoprotein as a Drug Target in the Treatment of Multidrug Resistant Cancer
- Monoclonal antibodies specific for P-glycoprotein. Okochi, E; Iwahashi, T; Tsuruo, T // Leukemia (08876924);Jul97, Vol. 11 Issue 7, p1119
Multidrug resistance (MDR) is one of the major obstacles to successful cancer chemotherapy. Since P-glycoprotein (P-gp) encoded by the MDR-1 gene plays a key role in MDR, many P-gp-specific monoclonal antibodies (MAbs) have been generated for characterization and analysis of P-gp. Among those...
- Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. Lehne, G; De Angelis, P; den Boer, M; Rugstad, H E // Leukemia (08876924);May99, Vol. 13 Issue 5, p768
The multidrug transporter P-glycoprotein (Pgp), which is frequently overexpressed in multidrug resistant leukemia, has many proposed physiological functions including involvement in transmembraneous transport of certain growth-regulating cytokines. Therefore, we studied cell growth of three...
- The equilibrium and kinetic drug binding properties of the mouse P-gp1a and P-gp1b P-glycoproteins are similar. Taylor, J C; Ferry, D R; Higgins, C F; Callaghan, R // British Journal of Cancer;11/1/99, Vol. 81 Issue 5, p783
The gene encoding the multidrug resistance P-glycoprotein (P-gp) is duplicated in rodent species and the functional basis for this remains unresolved. Despite a high sequence similarity, the mouse P-gp1a and P-gp1b isoforms show distinct patterns of tissue distribution which suggest a specific...
- Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging. Tatsumi, Mitsuaki; Tsuruo, Takashi; Nishimura, Tsunehiko // European Journal of Nuclear Medicine & Molecular Imaging;2002, Vol. 29 Issue 3, p288
MS-209 is a newly synthesised multidrug-resistance (MDR)-reversing agent with few side-effects. In this study, we evaluated the effect of MS-209 on P-glycoprotein (Pgp)-positive tumours in mice by means of technetium-99m methoxyisobutylisonitrile (MIBI) imaging. Mice received Pgp-negative KB-3-1...
- Clinical pharmacology. // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS12
Presents an abstract of the research manuscript `P-glycoprotein-mediated drug transport by Caco-2 cells,' by R.B. Kim, C. Wandel et al from the Vanderbilt University.
- Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia. Broxterman, H J; Lankelma, J; Pinedo, H M; Eekman, C A; W�hrer, D C R; Ossenkoppele, G J; Schuurhuis, G J // Leukemia (08876924);Jul97, Vol. 11 Issue 7, p1110
This paper summarizes experimental data and theoretical considerations, that are important for the measurement of P-glycoprotein (Pgp) function in acute myeloid leukemia (AML). The data are presented in subdivisions based on the techniques used, which will facilitate finding specific...
- Flow cytometric analysis of P-glycoprotein function using rhodamine 123. P�triz, J; Garc�a-L�pez, J // Leukemia (08876924);Jul97, Vol. 11 Issue 7, p1124
The MDR1 gene product, P-glycoprotein (P-gp), works as a transmembrane efflux pump for several cytotoxic products, representing a major cause for cancer treatment failure. Rhodamine 123 (Rh123), a low toxic fluorescent probe commonly used to assess mitochondrial bioenergetics in living cells,...
- Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Shukla, S.; Sauna, Z. E.; Ambudkar, S. V. // Leukemia (08876924);Feb2008, Vol. 22 Issue 2, p445
A letter to the editor is presented in response to an article on the role of P-glycoprotein in both in vitro and in vivo resistance to imatinib mesylate.
- P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. Speicher, Lisa A.; Barone, Linda R. // JNCI: Journal of the National Cancer Institute;5/4/94, Vol. 86 Issue 9, p688
Characterizes the interactions of the multidrug resistant phenotype by estramustine with P-glycoprotein. Photoaffinity labeling of membrane fractions; Competitive inhibition of proteins binding with estramustine; Concentration-dependent enhancement of drug accumulation.